Araştırma Makalesi

Levels of Serum and Urine Catecholaminergic and Apelinergic System Members in Acute Ischemic Stroke Patients

Cilt: 18 Sayı: 3 20 Kasım 2023
PDF İndir
EN TR

Levels of Serum and Urine Catecholaminergic and Apelinergic System Members in Acute Ischemic Stroke Patients

Abstract

Objective: To compare levels of catecholaminergic system members, renalase, cerebellin, and their substrates, epinephrine, norepinephrine, and dopamine, and apelinergic system members, apelin, elabela, and nitric oxide in the blood and urine of patients with acute ischemic stroke and healthy controls. Materials and Methods: 42 patients with acute ischemic stroke and 42 age and sex-matched healthy controls were included in the study. Blood and urine samples were collected simultaneously and within the first 24 hours after the onset of acute stroke clinical manifestations and were measured using an ELISA method. Results: The levels of serum and urine cerebellin, renalase, epinephrine, norepinephrine, dopamine, apelin, elebela, and nitric oxide were similar in ischemic stroke and in control groups (P>0.05). Strong correlations were found between renalase, cerebellin, and catecholamine levels in serum and urine (p <0.001) both in stroke patients and controls. There were also strong correlations between apelin, elabela, and NO levels in serum and urine (p <0.001) in the two groups. Conclusion: Serum and urine cerebellin, renalase, epinephrine, norepinephrine, dopamine, apelin, elebela, and nitric oxide levels do not significantly change in the acute phase of ischemic stroke. Strong correlations among renalase, cerebellin, and catecholamines emphasize that these substances act together in healthy individuals and ischemic stroke patients. Similarly, strong correlations between apelin, elabela, and NO indicate that these agents act together in healthy subjects and patients with ischemic stroke.

Keywords

ischemic stroke , renalase , cerebellin , epinephrine , norepinephrine , dopamine , apelin , elabela , nitric oxide

Kaynakça

  1. Katan M, Luft A. Global Burden of Stroke. Semin Neurol. 2018;38(2):208-211
  2. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. Future costs of strokein the : theimpact of stroke services. Int J Technol Assess Health Care. 2006;22(04):518–524
  3. Zerna C, Thomalla G, Campbell BCV, Rha JH, Hill MD. Current practice and future directions in the diagnosis and acute treatment of ischaemic stroke. Lancet. 201;392(10154):1247-1256.
  4. Rabinstein AA. Treatment of Acute Ischemic Stroke. Continuum (Minneap Minn). 2017;23(1, Cerebrovascular Disease):62-81.
  5. Patel RAG, McMullen PW. Neuroprotection in the Treatment of Acute Ischemic Stroke. Prog Cardiovasc Dis. 2017;59(6):542-548.
  6. Lundberg U. Stress hormones in health and illness: the roles of work and gender. Psychoneuroendocrinology. 2005;30(10):1017-1021.
  7. Goldstein DS, Eisenhofer G, Kopin IJ. Clinical catecholamine neurochemistry: a legacy of Julius Axelrod. Cell Mol Neurobiol. 2006;26(4-6):695-702.
  8. Mazzocchi G, Andreis PG, De Caro R, Aragona F, Gottardo L, Nussdorfer GG. Cerebellin enhances in vitro secretory activity of human adrenal gland. J Clin Endocrinol Metab. 1999;84(2):632-635.
  9. Rucinski M, Malendowicz LK. Precerebellin-related genes and precerebellin 1 peptide in endocrine glands of the rat-pattern of their expression. Int J Mol Med. 2009;23(1):113-119.
  10. Strowski MZ, Kaczmarek P, Mergler S, Wiedenmann B, Domin D, Szwajkowski P, et al. Insulinostatic activity of cerebellin-evidence from in vivo and in vitro studies in rats. Regul Pept. 2009;157(1-3):19-24.

Kaynak Göster

AMA
1.Güler Ö, Tuğan Yıldız B, Hakkoymaz H, Aydın S, Yardım M. Levels of Serum and Urine Catecholaminergic and Apelinergic System Members in Acute Ischemic Stroke Patients. KSÜ Tıp Fak Der. 2023;18(3):86-94. doi:10.17517/ksutfd.1168625